Thus, any AD therapeutic hoping to stop or reverse AD cognitive decline will probably need to penetrate the blood–brain barrier, then the brain’s neurons, and be able to disaggregate BOTH Aβ and tau oligomers, especially after the disease has become established. This evidence concerns the gene MAPT and Alzheimer disease.